当前位置: X-MOL 学术Int. Immunopharmacol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Profiles of tumor-infiltrating immune cells and prognostic genes associated with the microenvironment of bladder cancer.
International Immunopharmacology ( IF 5.6 ) Pub Date : 2020-05-26 , DOI: 10.1016/j.intimp.2020.106641
Faping Li 1 , Hui Guo 1 , Yishu Wang 2 , Bin Liu 1 , Honglan Zhou 1
Affiliation  

The immune microenvironment in bladder cancer (BC) and its significance still remain poorly understood. The present work aims to investigate tumor-infiltrating immune cells (TIICs) and prognostic genes associated with the tumor microenvironment (TME) of BC. The immune and stromal scores of BC samples from The Cancer Genome Atlas database were downloaded from the ESTIMATE website. Based on these scores, BC samples were assigned to the high and low score groups and 429 intersecting differentially expressed genes were identified. Functional enrichment analysis further revealed that these genes dramatically participated in the immune-related biological processes and signaling pathways. Two TME-related genes, angiotensin II receptor type 2 (AGTR2) and sclerostin domain containing 1 (SOSTDC1), were identified to establish an immune-related risk model using Cox regression analyses. Intriguingly, patients with high-risk scores had poor outcomes (p < 0.001). The areas under the curve for the risk model in predicting 3- and 5-year survival rates were 0.692 and 0.707, respectively. Kaplan-Meier survival analysis showed that the expression of AGTR2 and SOSTDC1 significantly correlated with the overall survival of BC patients. Additionally, 22 TIICs in the BC microenvironment were analyzed with the CIBERSORT algorithm. This study indicated that the effective components of TME affected the clinical outcomes of BC patients and might provide a basis for the development of new immunotherapies for BC patients.



中文翻译:

肿瘤浸润性免疫细胞的概况和与膀胱癌微环境相关的预后基因。

膀胱癌(BC)的免疫微环境及其意义仍然知之甚少。目前的工作旨在调查肿瘤浸润的免疫细胞(TIIC)和与BC的肿瘤微环境(TME)相关的预后基因。可从ESTIMATE网站下载来自The Cancer Genome Atlas数据库的BC样本的免疫和基质评分。基于这些分数,将BC样本分配给高分数组和低分数组,并鉴定出429个相交的差异表达基因。功能富集分析进一步表明,这些基因显着参与了免疫相关的生物学过程和信号通路。两个与TME相关的基因,血管紧张素II受体2型(AGTR2)和包含1的硬化素结构域(SOSTDC1),通过Cox回归分析确定了建立免疫相关风险模型的方法。有趣的是,高风险评分患者的预后较差(p <0.001)。用于预测3年和5年生存率的风险模型的曲线下面积分别为0.692和0.707。Kaplan-Meier生存分析表明AGTR2和SOSTDC1的表达与BC患者的总体生存率显着相关。此外,使用CIBERSORT算法分析了BC微环境中的22个TIIC。这项研究表明,TME的有效成分影响了BC患者的临床结局,并可能为开发针对BC患者的新免疫疗法提供基础。用于预测3年和5年生存率的风险模型的曲线下面积分别为0.692和0.707。Kaplan-Meier生存分析表明AGTR2和SOSTDC1的表达与BC患者的总体生存率显着相关。此外,使用CIBERSORT算法分析了BC微环境中的22个TIIC。这项研究表明,TME的有效成分影响了BC患者的临床结局,并可能为开发针对BC患者的新免疫疗法提供基础。用于预测3年和5年生存率的风险模型的曲线下面积分别为0.692和0.707。Kaplan-Meier生存分析表明AGTR2和SOSTDC1的表达与BC患者的总体生存率显着相关。此外,使用CIBERSORT算法分析了BC微环境中的22个TIIC。这项研究表明,TME的有效成分影响了BC患者的临床结局,并可能为开发针对BC患者的新免疫疗法提供基础。使用CIBERSORT算法分析了BC微环境中的22个TIIC。这项研究表明,TME的有效成分影响了BC患者的临床结局,并可能为开发针对BC患者的新免疫疗法提供基础。使用CIBERSORT算法分析了BC微环境中的22个TIIC。这项研究表明,TME的有效成分影响了BC患者的临床结局,并可能为开发针对BC患者的新免疫疗法提供基础。

更新日期:2020-05-26
down
wechat
bug